Drug
Brincidofovir
Brincidofovir: highest development phase Phase 3, developed by Emergent BioSolutions, Jazz Pharmaceuticals. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Emergent BioSolutions, Jazz Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Brincidofovir NCT02087306 | Phase 3 | Adenovirus Infection |
| Brincidofovir NCT01769170 | Phase 3 | CMV |
| Brincidofovir NCT00942305 | Phase 2 | Cytomegalovirus Infection |
| Brincidofovir NCT03339401 | Phase 2 | Adenovirus |
| Brincidofovir NCT01241344 | Phase 2 | Adenovirus Disease |
| Brincidofovir NCT05935917 | Phase 1 | Smallpox |
Latest
No recent events.
Follow Brincidofovir on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.